Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
366. |
ECCT/22/10/05 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Videlis N Nduba Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) |
View |
367. |
ECCT/22/11/02 | UNCPM 22120 5-FU Study UNCPM 22120: Safety of adjuvant, self-administered intravaginal 5-fluorouracil (5-FU) cream following cervical intraepithelial neoplasia grade 2 and 3 (CIN2/3) treatment among HIV-positive women in Kenya: A pilot study |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Chemtai Mungo Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) |
View |
368. |
ECCT/22/11/03 | BFAST A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya Aga Khan University, Nairobi |
View |
369. |
ECCT/22/11/04 | YWF:03 YWF:03: A PHASE III, MULTICENTER, DOUBLE BLIND, RANDOMIZED STUDY OF SII YELLOW FEVER VACCINE TO COMPARE SAFETY AND IMMUNOGENICITY WITH STAMARIL® |
Principal Investigator(s) 1. Videlis Nduba 2. Otieno Walter Site(s) in Kenya 1. KEMRI-CRDR (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
370. |
ECCT/22/12/01 | HIV & Tobacco Cessation Study Integrating Tobacco use cessation into HIV care and Treatment Clinics in Ministry of Health Facilities in Kisumu County, Kenya |
Principal Investigator(s) 1. Elizabeth Bukusi Site(s) in Kenya KEMRI-RCTP |
View |